Elicio Therapeutics, Inc. — Director's Dealing 2021

Feb 4, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Angion Biomedica Corp. (ANG)
CIK: 0001601485
Period of Report: 2021-02-04

Reporting Person: OMENN GILBERT S (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	18669	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$9.52	2030-02-13	Common Stock (38895)		Direct
Convertible Promissory Note	$11.57		Common Stock (23455)		Indirect
Convertible Promissory Note	$11.57		Common Stock (23362)		Indirect
Convertible Promissory Note	$11.57		Common Stock (14764)		Indirect

Footnotes

F1: Reflects a 1-to-1.55583 stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F2: Gilbert S. Omenn Revocable Trust.

F3: One thirty-six (1/36th) of the shares subject to the option will vest on each monthly anniversary measured from April 1, 2020 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date.

F4: The convertible promissory note has a maturity date of May 20, 2021, and the principal and accrued interest will convert immediately prior to the consummation of the IPO into Common Stock at a conversion price equal to $11.57 per share.

F5: The convertible promissory note has a maturity date of June 1, 2021, and the principal and accrued interest will convert immediately prior to the consummation of the IPO into Common Stock at a conversion price equal to $11.57 per share.

F6: The convertible promissory note has a maturity date of August 14, 2021, and the principal and accrued interest will convert immediately prior to the consummation of the IPO into Common Stock at a conversion price equal to $11.57 per share.